Key Highlights

  • Revenue in the fiscal 2027 second quarter grew 9%, reaching USD 1.6 billion, with 8% constant currency organic growth; as reported Net Income hit USD 213.7 million, or USD 2.19 per diluted share.
  • Adjusted EPS increased to USD 2.94 from USD 2.47, and Tariff refunds produced a pre-tax benefit of roughly USD 20 million on an as-reported basis during the quarter.
  • Guidance for fiscal 2027 adjusted EPS now stands at USD 11.35 to USD 11.55, raised from a previous USD 11.10 to USD 11.30, with roughly USD 0.18 attributable to tariff refunds collected so far this year.
  • Life Sciences Revenue advanced 18% to USD 170.6 million, and its organic growth outlook for the year was raised to 9% to 10% from 6% to 7%.

Tariff Refunds Layered Onto a Solid Quarter

STERIS (NYSE:STE) announced its quarter ending September 30, 2026 on November 4, 2026. As-reported net income came to USD 213.7 million, compared with USD 191.9 million, and adjusted net income reached USD 286.8 million, versus USD 244.5 million. Adjusted EPS strips out amortization of acquired intangibles, deal and integration costs, restructuring and other unusual items. Tariff refunds delivered a pre-tax benefit of about USD 20 million, while gross tariff costs held flat at USD 15 million. The USD 0.47 gain in adjusted EPS, a calculated figure, is therefore not entirely underlying. Management called the performance solid and anticipates another record year, citing Demand and commercial execution, although the release does not split the refund effect on quarterly EPS.

Life Sciences Leads as Applied Sterilization Technologies Cools

Healthcare revenue rose 9% to USD 1.1 billion, with service up 10%, consumables up 10% and Capital equipment up 4%, while Operating Income reached USD 269.2 million, compared with USD 259.5 million. Applied Sterilization Technologies revenue advanced 5% to USD 295.6 million, though capital equipment dropped 21% and operating income was USD 132.1 million. Life Sciences operating profit reached USD 75.8 million, against USD 59.9 million, thanks to pricing, productivity gains, Volume and product mix; capital equipment sales jumped 53%, consumables gained 9% and service revenue added 5%. Management lifted the segment's full-year organic growth outlook on that strength, but trimmed the AST organic growth outlook to 6% to 7% from 7% to 8%.

Restructuring Charges, Free Cash Flow and the Xodus Pending Deal

Fiscal 2027 revenue growth expectations hold at 7% to 8% as reported and 6% to 7% in constant currency organic terms. A second restructuring program, centered on Healthcare, carries about USD 45 million of charges, including USD 25 million booked in the quarter, and should Yield annualized savings of roughly USD 9 million. Free cash flow over six months came to USD 492.5 million, versus USD 527.7 million, because Working Capital added less; higher net income offset part of that drop. Six-month operating cash came to USD 656.1 million against USD 707.8 million. The proposed Xodus Medical Acquisition is not yet in the outlook, which will be revised after closing.

Where Things Stand

Only in part: roughly USD 0.18 of the outlook traces to refunds already received this year. STERIS (NYSE:STE) still grew revenue 9%, with Life Sciences and Healthcare services leading, and management presents the new USD 11.35 to USD 11.55 range as reflecting steady underlying results. Next markers are the November 5, 2026 conference call, closing of the Xodus Medical deal, restructuring savings and whether AST capital equipment recovers. The release gave no stock price reaction.